Ipsen, a French pharmaceutical company headquartered in Paris, acquired Clementia Pharmaceuticals, a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need, for $1.3bn. David Meek, Chief Executive Officer of Ipsen, commented, “The acquisition of Clementia Pharmaceuticals accelerates the ongoing transformation of Ipsen as we are successfully executing on our external innovation strategy to identify and acquire innovative medicines to serve patients with unmet medical needs. Through this transaction, we will gain scientific expertise, exceptional talent, and a cornerstone ultra-rare disease drug candidate with rare pediatric disease and breakthrough therapy designations, potential U.S. approval in 2020 and additional indications to follow.”